Currently, based on preclinical mechanistic cancer models and/or cancer patient-based data, potential therapeutic targets for tumors are being explored for different signaling pathways as well as biological processes, including immune checkpoints, as well as potential therapeutic targets such as mTOR, PARP, ATR, EZH2 and HDACs (Figure 3). This evidence concerns the gene EZH2 and cancer.